Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19234909 | 0.87 | SLC7A5 (0.66) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL19234901 | 0.87 | SLC7A5 (0.66) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL855080 | 0.86 | SLC7A5 (0.56) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL19234900 | 0.84 | SLC7A5 (0.54) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL19234912 | 0.84 | SLC7A5 (0.54) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL19234911 | 0.84 | SLC7A5 (0.54) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL19234894 | 0.84 | SLC7A5 (0.54) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL1932906 | 0.83 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL169646 | 0.83 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL4943107 | 0.83 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121249-A1 | ALPHA EMITTER LABELLED SOMATOSTATIN RECEPTOR ANTAGONISTS | ARICEUM THERAPEUTICS GMBH (DE) | 2024-06-13 | — | — | WO | disclosed |
| EP-2801582-B1 | Somatostatin receptor 2 antagonists | SALK INST FOR BIOLOGICAL STUDI (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-2801582-A1 | Somatostatin receptor 2 antagonists | Salk Institute For Biological Studies (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2383289-B1 | Receptor (SSTR2)-selective somatostatin antagonists | SALK INST FOR BIOLOGICAL STUDI (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2433963-B1 | Receptor (SSTR2)-selective somatostatin antagonists | SALK INST FOR BIOLOGICAL STUDI (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8501687-B2 | Receptor(SSTR2)-selective somatostatin antagonists | UNIVERSITAT BERN (CH) | 2013-08-06 | — | — | US | disclosed |
| EP-2076535-B1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | SALK INST FOR BIOLOGICAL STUDI (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2433963-A1 | Receptor (SSTR2)-selective somatostatin antagonists | The Salk Institute for Biological Studies (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110269683-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | UNIVERSITY HOSPITAL BASEL | 2011-11-03 | — | — | US | disclosed |
| EP-2383289-A1 | Receptor (SSTR2)-selective somatostatin antagonists | The Salk Institute for Biological Studies (US) | 2011-11-02 | — | — | EP | disclosed |
| US-7960342-B2 | Side effect reduction; block receptor function so they can be used in therapy; labeled with radioactive iodine; drug screening | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2268667-A2 | SOMATOSTATIN RECEPTOR 2 ANTAGONISTS | Salk Institute For Biological Studies (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009129311-A2 | SOMATOSTATIN RECEPTOR 2 ANTAGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2009-10-22 | — | — | WO | disclosed |
| EP-2076535-A2 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080299040-A1 | SOMATOSTATIN RECEPTOR 2 ANTAGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES UNIVERSITAT BERN UNIVERSITY HOSPITAL BASEL | 2008-12-04 | — | — | US | disclosed |
| US-20080260638-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008048942-A2 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260638-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | SSTR5, SSTR4, SSTR3 | SLC7A5 85/4885PTGS1 4381/4885ALPI 4180/4885 |
| US-20110269683-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | SSTR5, SSTR4, SSTR3 | SLC7A5 129/4885PTGS1 4598/4885ALPI 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.